Jeffrey J Legos

Summary

Affiliation: GlaxoSmithKline Research and Development
Country: USA

Publications

  1. ncbi Update on pharmacological strategies for stroke: prevention, acute intervention and regeneration
    Jeffrey J Legos
    GlaxoSmithKline, PO Box 1539, 709 Swedeland Road, King of Prussia, Pa 19406 0939, USA
    Curr Opin Investig Drugs 4:847-58. 2003
  2. ncbi Programmable microchip monitoring of post-stroke pyrexia: effects of aspirin and paracetamol on temperature and infarct size in the rat
    Jeffrey J Legos
    GlaxoSmithKline, High Throughput Biology, Discovery Research, 709 Swedeland Road, PO Box 1539, King of Prussia, PA 19406, USA
    J Neurosci Methods 113:159-66. 2002
  3. ncbi Pharmacological interventions for stroke: failures and future
    Jeffrey J Legos
    High Throughput Biology, Discovery Research, GlaxoSmithKline, King of Prussia, PA, USA
    Expert Opin Investig Drugs 11:603-14. 2002
  4. ncbi The selective p38 inhibitor SB-239063 protects primary neurons from mild to moderate excitotoxic injury
    Jeffrey J Legos
    High Throughput Biology, Discovery Research, GlaxoSmithKline, PO Box 1539, Mail Code UW 2523, 709 Swedeland Road, 19406, King of Prussia, PA, USA
    Eur J Pharmacol 447:37-42. 2002
  5. ncbi SB 234551 selective ET(A) receptor antagonism: perfusion/diffusion MRI used to define treatable stroke model, time to treatment and mechanism of protection
    Jeffrey J Legos
    High Throughput Biology, Discovery Research, King of Prussia, PA, USA
    Exp Neurol 212:53-62. 2008
  6. ncbi Selective CETP inhibition and PPARalpha agonism increase HDL cholesterol and reduce LDL cholesterol in human ApoB100/human CETP transgenic mice
    Michael K Hansen
    Discovery Research, GlaxoSmithKline, King of Prussia, PA, USA
    J Cardiovasc Pharmacol Ther 15:196-202. 2010
  7. ncbi Non-surgical management of spinal cord injury
    Jeffrey J Legos
    Hign Throughput Biology, Discovery Research, GlaxoSmithKline, King of Prussia, PA, USA
    Expert Opin Investig Drugs 11:469-82. 2002
  8. ncbi Selective PPARdelta agonist treatment increases skeletal muscle lipid metabolism without altering mitochondrial energy coupling: an in vivo magnetic resonance spectroscopy study
    Beat M Jucker
    Cardiovascular and Urogenital Center of Excellence for Drug Discovery, GlaxoSmithKline, UW2510, King of Prussia, PA 19406, USA
    Am J Physiol Endocrinol Metab 293:E1256-64. 2007
  9. ncbi Inhibition of phosphodiesterase type 4 decreases stress-induced defecation in rats and mice
    Frank C Barone
    Discovery Research, High Throughput Biology, GlaxoSmithKline, King of Prussia, PA 19406, USA
    Pharmacology 81:11-7. 2008
  10. ncbi LEX032, a novel recombinant serpin, protects the brain after transient focal ischemia
    Michael Weaver
    Department of Physiology, Temple University School of Medicine, 3420 N. Broad St, Philadelphia, Pennsylvania 19140, USA
    Microvasc Res 63:327-34. 2002

Detail Information

Publications11

  1. ncbi Update on pharmacological strategies for stroke: prevention, acute intervention and regeneration
    Jeffrey J Legos
    GlaxoSmithKline, PO Box 1539, 709 Swedeland Road, King of Prussia, Pa 19406 0939, USA
    Curr Opin Investig Drugs 4:847-58. 2003
    ..e., neurobehavioral recovery) following brain damage...
  2. ncbi Programmable microchip monitoring of post-stroke pyrexia: effects of aspirin and paracetamol on temperature and infarct size in the rat
    Jeffrey J Legos
    GlaxoSmithKline, High Throughput Biology, Discovery Research, 709 Swedeland Road, PO Box 1539, King of Prussia, PA 19406, USA
    J Neurosci Methods 113:159-66. 2002
    ..However, a full characterization of these pyretic changes and the effects of anti-pyretic drugs on outcome is not available...
  3. ncbi Pharmacological interventions for stroke: failures and future
    Jeffrey J Legos
    High Throughput Biology, Discovery Research, GlaxoSmithKline, King of Prussia, PA, USA
    Expert Opin Investig Drugs 11:603-14. 2002
    ..The scope of this review will focus on recent clinical failures in addition to agents currently in clinical development, comparing vascular targets to the common neuroprotective strategies...
  4. ncbi The selective p38 inhibitor SB-239063 protects primary neurons from mild to moderate excitotoxic injury
    Jeffrey J Legos
    High Throughput Biology, Discovery Research, GlaxoSmithKline, PO Box 1539, Mail Code UW 2523, 709 Swedeland Road, 19406, King of Prussia, PA, USA
    Eur J Pharmacol 447:37-42. 2002
    ....
  5. ncbi SB 234551 selective ET(A) receptor antagonism: perfusion/diffusion MRI used to define treatable stroke model, time to treatment and mechanism of protection
    Jeffrey J Legos
    High Throughput Biology, Discovery Research, King of Prussia, PA, USA
    Exp Neurol 212:53-62. 2008
    ..In addition, tissue perfusion information obtained under these conditions might clarify mechanism of protection in the evaluation of protective compounds for focal stroke...
  6. ncbi Selective CETP inhibition and PPARalpha agonism increase HDL cholesterol and reduce LDL cholesterol in human ApoB100/human CETP transgenic mice
    Michael K Hansen
    Discovery Research, GlaxoSmithKline, King of Prussia, PA, USA
    J Cardiovasc Pharmacol Ther 15:196-202. 2010
    ..In addition, these data demonstrate the use of hApoB100/hCETP transgenic mice to identify, characterize, and screen compounds that increase HDL cholesterol...
  7. ncbi Non-surgical management of spinal cord injury
    Jeffrey J Legos
    Hign Throughput Biology, Discovery Research, GlaxoSmithKline, King of Prussia, PA, USA
    Expert Opin Investig Drugs 11:469-82. 2002
    ..This review summarises recent advances in the development of pharmacological agents targeting the acute phase of spinal cord injury as well as potential strategies to facilitate regeneration of the spinal cord...
  8. ncbi Selective PPARdelta agonist treatment increases skeletal muscle lipid metabolism without altering mitochondrial energy coupling: an in vivo magnetic resonance spectroscopy study
    Beat M Jucker
    Cardiovascular and Urogenital Center of Excellence for Drug Discovery, GlaxoSmithKline, UW2510, King of Prussia, PA 19406, USA
    Am J Physiol Endocrinol Metab 293:E1256-64. 2007
    ..However, the mitochondrial-energy coupling efficiency was not altered in the presence of increased uncoupling protein expression...
  9. ncbi Inhibition of phosphodiesterase type 4 decreases stress-induced defecation in rats and mice
    Frank C Barone
    Discovery Research, High Throughput Biology, GlaxoSmithKline, King of Prussia, PA 19406, USA
    Pharmacology 81:11-7. 2008
    ..In this study, the effects of PDE4 inhibition were assessed in a model of stress-induced defecation previously demonstrated to be due to increased colonic transit/evacuation...
  10. ncbi LEX032, a novel recombinant serpin, protects the brain after transient focal ischemia
    Michael Weaver
    Department of Physiology, Temple University School of Medicine, 3420 N. Broad St, Philadelphia, Pennsylvania 19140, USA
    Microvasc Res 63:327-34. 2002
    ..6 +/- 0.7). This data demonstrates that LEX032 reduces brain injury and suggests that serine protease inhibitors may reduce ischemia/reperfusion injury by decreasing leukocyte activation and migration...
  11. ncbi Caspase 3 activation is essential for neuroprotection in preconditioning
    BethAnn McLaughlin
    Department of Neurobiology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA
    Proc Natl Acad Sci U S A 100:715-20. 2003
    ..We outline a neuroprotective pathway where events normally associated with apoptotic cell death are critical for cell survival...